Lisa Anne Collins-Racie

USPTO Granted Patents = 16 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.7

ph-index = 5

Forward Citations = 63(Granted Patents)

Company Filing History:

Ono Pharmaceutical Co., Ltd.

patents

Years Active: 2006-2019

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10189896 - Antibody to GDF8 and uses thereof (2019-01-29),

2. 9850301 - Antibody to GDF8 and uses thereof (2017-12-26),

3. 9409981 - Antibody to GDF8 and uses thereof (2016-08-09),

4. 8987205 - Polynucleotides encoding recombinant lubricin molecules and uses thereof (2015-03-24),

5. 8420793 - Polynucleotides encoding recombinant lubricin molecules and uses thereof (2013-04-16),

6. 8415459 - Antibody to GDF8 and uses thereof (2013-04-09),

7. 7897571 - Recombinant lubricin molecules and uses thereof (2011-03-01),

8. 7893029 - Recombinant lubricin molecules and uses thereof (2011-02-22),

9. 7642236 - Recombinant lubricin molecules and uses thereof (2010-01-05),

10. 7638482 - Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases (2009-12-29),

11. 7625731 - Aggrecanase structure (2009-12-01),

12. 7615363 - Aggrecanase structure (2009-11-10),

13. 7344861 - Secreted proteins and polynucleotides encoding them (2008-03-18),

14. 7223858 - Truncated aggrecanase molecules (2007-05-29),

15. 7150983 - Truncated aggrecanase molecules (2006-12-19),

Title: Lisa Anne Collins-Racie: Pioneering Innovations in Biopharmaceuticals

Introduction: Lisa Anne Collins-Racie, an accomplished inventor hailing from Acton, MA, has made significant contributions to the field of biopharmaceuticals through her 16 patents. Her innovative work primarily focuses on growth and differentiation factor-8 (GDF8), which has critical implications for treating various disorders.

Latest Patents: One of her notable patents, titled "Antibody to GDF8 and Uses Thereof," presents novel molecules related to GDF8. This invention includes specific epitopes and antagonists, particularly anti-GDF8 antibodies, which possess the ability to inhibit GDF8 activity and signal in both in vitro and in vivo environments. Moreover, the patent outlines an immunoassay for detecting and quantifying GDF8 levels. Additionally, it describes methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, such as degenerative conditions related to muscle, bone, and insulin metabolism. The patent further encompasses pharmaceuticals developed from these inventions, including antibodies, polypeptides, polynucleotides, and vectors aimed at treating these disorders.

Career Highlights: Lisa has made her mark in prestigious companies within the pharmaceutical industry. She has worked with Wyeth and Pfizer Corporation, where she has been involved in research and development that influence the course of medical treatments.

Collaborations: Throughout her career, Lisa has collaborated with respected colleagues, such as Christopher John Corcoran and Bethany Annis Freeman. These collaborations have contributed to the advancement of her research and the successful development of her patented innovations.

Conclusion: Lisa Anne Collins-Racie continues to be a driving force in the biopharmaceutical sector, utilizing her expertise to advance medical treatments through her patents. Her contributions reflect not only her dedication as an inventor but also her impact on improving patient care through innovative science.

This text is generated by artificial intelligence and may not be accurate.